¼¼°èÀÇ ¼Ò¾Æ¿ë ¹é½Å ½ÃÀå ¿¹Ãø(2024-2029³â)
Global Pediatric Vaccine Market - Forecasts from 2024 to 2029
»óǰÄÚµå : 1496018
¸®¼­Ä¡»ç : Knowledge Sourcing Intelligence
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 130 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,950 £Ü 5,577,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,550 £Ü 6,424,000
PDF (Multiple User License) help
PDF º¸°í¼­¸¦ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,813,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼Ò¾Æ¿ë ¹é½Å ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 7.03%·Î È®´ëµÉ Àü¸ÁÀ̸ç 2022³â 309¾ï 2,000¸¸ ´Þ·¯¿¡¼­ 2029³â¿¡´Â 495¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¾ÆÀ̵鿡 ´ëÇÑ ¹é½Å Á¢Á¾°ú ¿¹¹æ Á¢Á¾Àº ¼±Áø ÀÇ·áÀÇ Áß¿äÇÑ ±¸¼º ¿ä¼ÒÀ̸ç, ¸¹Àº ¹é½ÅÀÌ ÈçÇÑ °æ¿ì¿¡µµ Áö¿ª¿¡ µû¶ó ¾à°£ º¯ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ¹é½ÅÀº ¾î¸°À̵éÀÌ Áúº´°ú Á¢ÃËÇϱâ Àü¿¡ Áúº´À¸·ÎºÎÅÍ ÀÚ½ÅÀ» º¸È£ÇϱâÀ§ÇÑ ¹æ¾î·Â°ú ¸é¿ª·Â(º¸Áõ·Â)À» Ű¿ì´Â °ÍÀ» Áö¿øÇÔÀ¸·Î½á ¾î¸°À̸¦ ´Ù¾çÇÑ Áúº´À¸·ÎºÎÅÍ º¸È£Çϱâ À§ÇØ Áö¿øÀ» Á¦°øÇÕ´Ï´Ù. ÀÎüÀÇ ÀϹÝÀûÀÎ ¹æ¾î, Áï ÀÚ¿¬ ¹æ¾î¸¦ °­È­ÇÔÀ¸·Î½á, ¹é½Å¿¡ Æ÷ÇÔµÈ Ç×ü´Â ÀÎü°¡ À§ÇèÇÑ °¨¿°°ú ½Å¼ÓÇϰí ÀûÀýÇÏ°Ô ½Î¿ï ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù.

¹é½ÅÀº ¸Å¿ì À̸¥ ½Ã±âºÎÅÍ Á¢Á¾µË´Ï´Ù. ¾î¸°ÀÌÀÇ ÀúÇ×°ú ¸é¿ª ü°è´Â ½É°¢ÇÑ Áúº´°ú °¨¿°°ú ½Î¿ì´Â µ¥ ÇʼöÀûÀÎ ÀúÇ×ÀÌ ¿©ÀüÈ÷ ¹ß´Þ ´Ü°è¿¡ Àֱ⠶§¹®¿¡ °¨¿°ÀÇ À§ÇèÀÌ È®´ëµË´Ï´Ù. ÀÌ Áõ°¡´Â ¿¹¹æ Á¢Á¾ÀÇ Á߿伺¿¡ ´ëÇÑ »ç¶÷µéÀÇ ÀǽÄÀÌ Áõ°¡Çϰí Àֱ⠶§¹®À̶ó°í »ý°¢µË´Ï´Ù. ¶ÇÇÑ ¹é½ÅÀÇ Á¶»ç¿Í °³Ã´¿¡ ´ëÇÑ Á¤ºÎ ¹× ºñÁ¤ºÎ·ÎºÎÅÍÀÇ º¸Á¶±Ý Áõ°¡´Â ÇâÈÄ ¼ö³â°£ ¼Ò¾Æ¿ë ¹é½Å»ê¾÷À» ´õ¿í ¼ºÀå½Ãų °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ:

CDC´Â 2¼¼ ¹Ì¸¸ÀÇ ¸ðµç ¾Æµ¿¿¡°Ô Æó·Å±¸±Õ °áÇÕ ¹é½Å(PCV13 ¶Ç´Â Prevnar13)À» Á¢Á¾ÇÏ´Â ÀÏÁ¤À» Á¦¾ÈÇÕ´Ï´Ù.

¸é¿ª¹ÝÀÀÀÇ °³¼±, ¼Ò¾ÆÀÇ ±Ø´ÜÀûÀÎ °¨¿°ÁõÀÇ È¸ÇÇ, ¹é½Å°èȹÀÇ ÅëÇÕ, Á¢Á¾ ÇÁ·Î±×·¥ÀÇ °³¹ß¿¡ ÀÇÇØ °áÇÕÇü ¿¹¹æÁ¢Á¾ ºÎ¹®ÀÇ È®´ë°¡ ¿¹»óµË´Ï´Ù. °áÇÕÇü ¿¹¹æÁ¢Á¾Àº ¾àÇÑ Ç׿ø°ú ij¸®¾î ´Ü¹éÁúÀÇ Á¶ÇÕÀ¸·Î ½Å»ý¾Æ¿Í À¯¾Æ¿¡°Ô Å« È¿°ú¸¦ ¹ßÈÖÇÕ´Ï´Ù. ÀÎÇ÷翣ÀÚ±Õ bÇü(Hib), Æó·Å±¸±Õ, ¼ö¸·¿°±Õ µî ¼Ò¾Æ¿¡¼­ ÀÚÁÖ º¸ÀÌ´Â ±Ø´ÜÀûÀÎ °¨¿°ÀÇ ¿¹¹æ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

¸¹Àº ³ª¶ó¿¡¼­´Â ¼Ò¾Æ±â °¨¿° ¿¹¹æÀÇ Á߿伺¿¡¼­ ¼Ò¾Æ°úÀÇ ¿¹¹æÁ¢Á¾ °èȹ¿¡ °áÇÕÇü ¿¹¹æÁ¢Á¾À» ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. WHO¿Í À¯´Ï¼¼ÇÁ °°Àº Á¶Á÷¿¡ ÀÇÇÑ ¼¼°è °Ç°­ º¹Áö Ȱµ¿°ú ÀÌ´Ï¼ÅÆ¼ºê´Â ¼Ò¾ÆÀÇ °Ç°­À» ¿ì¼±Çϰí Ç×üÀÇ Æø³ÐÀº ÀÌ¿ëÀ» Á¦Ã¢Çϰí ÀÖ½À´Ï´Ù. ±¹¹Î°£ÀÇ ÀǽÄÀÇ °íÁ¶, Áøº¸, Á¤ºÎ¿¡ ÀÇÇÑ ¿¬±¸°³¹ß Áö¿øÀÇ ÃßÁø, °øÁßÀ§»ýÀÇ Çâ»ó¿¡ ÇÊ¿äÇÑ ¼Ò¾Æ ¿¹¹æÁ¢Á¾ÀÇ ÀϹÝÀûÀÎ ¿ì¼±¼øÀ§È­´Â °áÇÕÇü ¹é½Å »ê¾÷¿¡¼­ÀÇ È®´ë¸¦ ÃËÁøÇÑ´Ù°í ¿¹»óµË´Ï´Ù.

¼±Áø±¹»Ó¸¸ ¾Æ´Ï¶ó °³¹ßµµ»ó±¹µµ ¼Ò¾Æ ¿¹¹æÁ¢Á¾ÀÇ ÁøÂû·ü Çâ»ó¿¡ ÀÓÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¼¼°è ¼Ò¾Æ ¹é½Å »ê¾÷ÀÇ È®´ë¿¡ Å« ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¼Ò¾ÆÀÇ ÀÎÇ÷翣ÀÚ, ¹éÀÏÇØ, ·ÏÁ¶, µðÇÁÅ׸®¾Æ µîÀÇ °¨¿°À̳ª ºñ°¨¿°ÁõÀÇ À¯Ç൵ ÀÌ ½ÃÀåÀ» ºñ¾àÀûÀ¸·Î È®´ë½ÃŰ´Â Å« ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ Àεµ µî Àα¸ Áõ°¡·Î ¼¼°è ¾î¸°ÀÌ Àα¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ 2020³â À¯´Ï¼¼ÇÁÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é Àεµ¿¡¼­´Â ¸ÅÀÏ 67,385¸íÀÇ ¾Æ±â°¡ ž°í ÀÖÀ¸¸ç, ÀÌ´Â ¼¼°è Ãâ»êÀÇ 1/6À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ½Å»ý¾Æ¿Í ¼Ò¾Æ Àα¸ Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ¼Ò¾Æ ¹é½Å »ê¾÷À» À̲ø °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ¼Ò¾Æ¿ë ¹é½Å ½ÃÀåÀº ºÏ¹Ì°¡ Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´ë±Ô¸ð ¿¬±¸°³¹ßºñ, ÃÖ÷´Ü ÀÇ·á½Ã¼³¿¡ÀÇ ¿ëÀÌÇÑ Á¢±Ù, Áß¿äÇÑ ½ÃÀå°æÀï »ó´ëÀÇ Á¸Àç, ÀϹݽùÎÀÇ ÀÇ·áÁúȯ¿¡ ´ëÇÑ ³ôÀº ÀÇ½Ä µîÀÌ ÃÖ´ë ºñÀ²À» Â÷ÁöÇÏ´Â ¿äÀÎÀ̶ó°í »ý°¢µË´Ï´Ù.

ƯÈ÷ Àεµ¿Í Áß±¹°ú °°Àº ¼ºÀå °æÁ¦±Ç¿¡¼­´Â °Ç°­ °ü¸®¸¦ ÃËÁøÇϱâ À§ÇÑ Á¤ºÎ Á¤Ã¥ÀÌ °­È­µÇ¾î ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ ¿¹Ãø ±â°£ µ¿¾È ÃÖ´ë º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î Àεµ Á¤ºÎ°¡ È¿°úÀûÀÌ°í ¼º°øÀûÀ¸·Î ½Ç½ÃÇÑ Æú¸®¿À ¹é½Å Á¢Á¾Àº ±¹³»¿¡¼­ °¡Àå ¼º°øÀûÀÎ ¼Ò¾Æ ¹é½Å Á¢Á¾ Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ ¼Ò¾Æ »ç¸Á·üÀ» ³·Ãß±â À§ÇØ Àεµ´Â 2021³â 12¿ù Æó·Å±¸±Õ È¥ÇÕ ¹é½ÅÀÇ Á¢Á¾ ¹üÀ§¸¦ È®´ëÇÏ¿© PCV13ÀÇ Á¢Á¾À» ÅëÇÕÇß½À´Ï´Ù.

ÁÖ¿ä ¹ßÀü:

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

Á¦5Àå ¼Ò¾Æ¿ë ¹é½Å ½ÃÀå : ¹é½Å À¯Çüº°

Á¦6Àå ¼Ò¾Æ¿ë ¹é½Å ½ÃÀå : ±â¼úº°

Á¦7Àå ¼Ò¾Æ¿ë ¹é½Å ½ÃÀå : ¿ëµµº°

Á¦8Àå ¼Ò¾Æ¿ë ¹é½Å ½ÃÀå :Áö¿ªº°

Á¦9Àå °æÀï ȯ°æ°ú ºÐ¼®

Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global pediatric vaccine market is expected to expand at a CAGR of 7.03% during the projected period to attain US$49.550 billion by 2029, up from US$30.920 billion in 2022.

Vaccination and immunization of children are vital constituents of advanced medication and may change marginally depending upon the area, indeed in spite of the fact that numerous vaccines are common. These vaccines offer assistance to safeguard children from different illnesses by supporting them to grow defense and immunity (assurance) that protects them against illnesses prior to they come into contact with them. By fortifying the human body's common protections i.e. natural defenses, the antibodies in the vaccines allow the human body to battle dangerous infections quickly and more competently.

Vaccines are begun at a very early age. Children are at expanded risk for infectious illnesses since their resistant mechanisms and immune systems are still in the developing phase the essential resistances to battle severe diseases and infections. The boost may be credited to the increasing public awareness among individuals concerning the significance of immunization. An increment in government and non-government subsidizing for the investigation and advancement of vaccines will moreover increase the industry for pediatric vaccines in the years ahead, at the same time, the high price of the vaccine could obstruct the market development in the coming years.

Market Drivers:

Conjugate vaccines are chemically attached antigens to carrier proteins, converting them into T-dependent antigens that elicit robust immune responses in infants and adults The CDC suggests the schedule direction for pneumococcal conjugate immunization (PCV13 or Prevnar13) for all children that are under two years of age.

The conjugate immunization segment's extension is anticipated due to improved immune reaction, avoidance of extreme infections in children, incorporated vaccine plans, and development of inoculation programs. Conjugate immunizations are profoundly successful in newborn children and young children because of their weak antigen's combination with a carrier protein. They play a pivotal part in anticipating extreme infectious illnesses commonly influencing children, such as Haemophilus influenzae type b (Hib), Streptococcus pneumoniae, and Neisseria meningitidis.

Numerous nations have consolidated conjugate immunizations into their pediatric immunization plans, reflecting their significance in avoiding infections amid early childhood. Global health well-being activities and initiatives by organizations, like WHO and UNICEF, prioritize health of child and advocate for the broad utilization of antibodies. growing awareness among the public, progressing advancement, in R&D supportive drive by the government, and the general prioritization of pediatric immunization as a necessity for improved public well-being is anticipated to drive expansion within the conjugate vaccine industry.

Developing as well as developed nations are taking action to improve admittance to pediatric immunization, which is anticipated to emphatically affect the worldwide pediatric vaccine industry expansion. Besides, the predominance of various infections, such as flu, pertussis, lockjaw, and diphtheria, among other infectious diseases as well as non-infectious diseases in children is however another major cause driving this market exponentially.

Also, the rising populace of nations such as India is expanding up to the population of children all over the globe. Further, as per UNICEF data for 2020, 67,385 babies are born in India each day, which accounts for one-sixth of the world's childbirth. Thus, the rising newborn child and children populace is anticipated to drive the worldwide pediatric vaccine industry amid the projected period.

The global pediatric vaccines market is expected to be dominated by the North American region, which is expected to hold a significant share of the pediatric vaccine market. Large-scale R&D expenditures, easy access to cutting-edge medical facilities, the presence of significant market competitors, and the general public's high degree of medical disease awareness may all contribute to the biggest proportion.

Due to increased government policies to promote healthcare, especially in growing economies like India and China, Asia-Pacific is anticipated to expand at the greatest CAGR over the forecast period. For instance, India's effective and successful polio vaccination drive presented by the government of India is one of the foremost successful pediatric vaccination drives within the nation. Moreover, with the intention to lower childhood mortality, India expanded its Pneumococcal Conjugate immunization scope in December 2021 to incorporate the PCV13 immunization.

Key Development:

Market Segmentation:

The Global Pediatric Vaccine Market is segmented and analyzed as below:

By Vaccine Type

By Technology

By Application

By Geography

TABLE OF CONTENTS

1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

5. GLOBAL PEDIATRIC VACCINE MARKET BY VACCINE TYPE

6. GLOBAL PEDIATRIC VACCINE MARKET BY TECHNOLOGY

7. GLOBAL PEDIATRIC VACCINE MARKET BY APPLICATION

8. GLOBAL PEDIATRIC VACCINE MARKET BY GEOGRAPHY

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

10. COMPANY PROFILES

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â